Table 2.

Activity and response of each combination treatment in the KB tumor nu/nu mouse tumor model

AMWL
Treatment regimenPR%CR%Cures%LCK%PTI (d)
Control mice with KB tumors 100003 ± 2.29–11
Control mice with KB tumors 200001.3 ± 1.77–17
Vintafolide (1 μmol/kg TIW × 2)00200.60.8 ± 1.39–11
Cisplatin (3 mg/kg BIW × 2)40001.810.5 ± 4.512–19
Vintafolide (1 μmol/kg TIW × 2) + Cisplatin (3 mg/kg BIW × 2)0010011.9 ± 4.412–24
Vintafolide (1 μmol/kg TIW × 2)0001.10.4 ± 0.98–15
Carboplatin (50 mg/kg TIW)600025.9 ± 1.713–15
Vintafolide (1 μmol/kg TIW × 2) + Carboplatin (50 mg/kg TIW)020804.45.3 ± 2.711–15
Vintafolide (1 μmol/kg TIW × 2)800201.71.3 ± 1.56–20
Paclitaxel (40 mg/kg SIW × 3)40002.32.3 ± 2.26–11
Vintafolide (1 μmol/kg TIW × 2) + Paclitaxel (40 mg/kg SIW × 3)060402.52.8 ± 2.96–15
Vintafolide (1 μmol/kg TIW × 2)00200.60.8 ± 1.39–11
Docetaxel (10 mg/kg TIW)0001.216.3 ± 4.416–23
Vintafolide (1 μmol/kg TIW × 2) + Docetaxel (10 mg/kg TIW)0010010.5 ± 3.216–21
Vintafolide (1 μmol/kg TIW × 2)00200.60.8 ± 1.39–11
Topotecan (5 mg/kg TIW × 2)0000.611.8 ± 5.79–22
Vintafolide (1 μmol/kg TIW × 2) + Topotecan (5 mg/kg TIW × 2)604002.46.7 ± 5.520
Vintafolide (1 μmol/kg TIW × 2)0001.10.8 ± 1.010–12
Irinotecan (20 mg/kg BIW × 2)0001.01.2 ± 1.08–9
Vintafolide (1 μmol/kg TIW × 2) + Irinotecan (20 mg/kg BIW × 2)040604.31.4 ± 1.58–14